{
  "docId": "019de077-691b-72c2-80d2-a28de652ce70",
  "docSlug": "7b833127c4e1241e21c155446b1ba76b",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 42,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a structured list format to present safety outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-691b-72c2-80d2-a28de652ce70/37",
  "deckHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70",
  "deckJsonHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70.json",
  "deckAnchorHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.26,
        "y": 0.22
      },
      "kind": "list",
      "text": "Virtually all (99%) adverse events (AEs) were mild-to-moderate in severity; Minimal (2.5%) treatment emergent AEs (TEAEs) led to study withdrawal; No drug-related serious adverse events (SAEs)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6eb4e4f5-2ba5-45f0-b913-1a11db0263da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.26,
        "y": 0.62
      },
      "kind": "list",
      "text": "No suicidal or self-injurious behavior; ≤ 2 participants per arm reported suicidal ideation during the study; No indication of increased suicidality or suicide-related risk",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bd57df1-4e1a-4df5-ada2-059480034bec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.26,
        "y": 0.45
      },
      "kind": "list",
      "text": "Only SAE was in 50 µg dose group and deemed unrelated; AE profile consistent with historical studies and drug class",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e27bbeee-9420-48f8-92f7-f93aaea06796",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Source: Study MMED008 internal study documents and calculations. Safety population. 2. One serious adverse event (SAE) was observed in the 50 µg dose group: panic attack on study day 98 that was deemed not related to treatment. 3. Suicidality assessment based on reported adverse events.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8a46ebd-05f9-48fa-ab20-ef2886edc83b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "MM120 was Well-tolerated with Mostly Transient, Mild-to-Moderate Adverse Events Consistent with Drug Class Expectations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2185c142-ae53-4836-b95f-486d0a9d07f7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f0b38644-7847-4291-9e14-d29efeca0864",
      "evidence": "The slide uses a list/bullet format to present information.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 42,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6a4562d9-e1ba-4048-9ae4-0523b32c6d36",
      "evidence": "The document follows the golden circle framework, starting with the company's vision (why) and presenting its approach (how) and solution (what).",
      "position": 1,
      "objective": "Presenting the company's vision and approach",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}